16 completed, 3 unknown, 2 terminated, 1 recruiting. 23 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 16, Unknown 3, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow microcrystalline cellulose: new trials by email Literature Review of microcrystalline cellulose trials Research Report on microcrystalline cellulose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults Nezavist SDD, Placebo - Healthy, Safety Evaluation of Escalating Doses | Phase 1 | Terminated | Lohocla Research Corporation | 29 | 2025-02-28 | 2026-09-08 |
| Nicotinic Acid for the Treatment of Alzheimer's Disease Placebo Comparator, Extended Release Niacin - Alzheimer Disease | Phase 1 / Phase 2 | Recruiting | Indiana University | 30 | 2024-12-19 | 2026-03-05 |
| Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics Trimebutine, Lactobacillus rhamnosus, Placebo - Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders | Phase 1 / Phase 2 | Unknown | Universidad de Colima | 82 | 2024-09-01 | 2024-08-16 |
| Effect of Alpelisib in Healthy Volunteers Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 23 | 2023-05-09 | 2023-12-21 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 | |
| A Phase I Study of GT300 in Healthy Subjects GT300, Microcrystalline cellulose - Lewy Body Disease | Phase 1 | Unknown | Generian Pharmaceuticals, Inc. | 56 | 2021-08-23 | 2021-07-15 |
| Application of Probiotic PS128 in Children With ASD probiotics PS128, placebo (Microcrystalline cellulose ) - Autism Spectrum Disorder | Phase 1 | Unknown | Yan Hao | 80 | 2021-06-06 | 2022-08-31 |
| A Study of Oral Ibogaine in Opioid Withdrawal DMX-1002, Placebo - Opiate Withdrawal Syndrome | Phase 1 / Phase 2 | Completed | atai Therapeutics, Inc. | 116 | 2021-04-01 | 2024-08-06 |
| Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease Contraloid acetate, Placebo - Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 1 | Completed | Charite University, Berlin, Germany | 19 | 2020-12-08 | 2022-08-23 |
| Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule - Type1 Diabetes | Phase 1 | Completed | Immunomolecular Therapeutics, Inc. | 30 | 2020-11-09 | 2021-08-25 |
| Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid Clavulanic Acid, Placebo - Cocaine Dependence | Phase 1 | Completed | Temple University | 13 | 2020-09-01 | 2023-06-22 |
| Effect of a Ghrelin Receptor Agonist on Muscle and Bone Anamorelin Hydrochloride, Placebo - Sarcopenia, Osteopenia | Phase 1 | Completed | Tufts University | 32 | 2019-12-05 | 2024-03-27 |
| Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease Dronabinol 2.5 MG, Microcrystalline cellulose - Sickle Cell Disease | Phase 1 | Terminated | Yale University | 6 | 2019-07-26 | 2021-01-26 |
| Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 XPF-008, Microcrystalline Cellulose - Healthy Male Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 20 | 2018-02-13 | 2018-09-18 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. XPF-008, Microcrystalline Cellulose, XPF-010 - Healthy Volunteers | Phase 1 | Completed | Xenon Pharmaceuticals Inc. | 130 | 2017-11-13 | 2023-05-11 |
| Effect of Vitamin D3 on Lung Function and Exercise Tolerance in COPD Patients Cholecalciferol - Stable COPD Patients | Phase 1 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 48 | 2017-03-01 | 2019-01-10 |
| Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects OMT-28, Matching Placebo - Healthy Volunteers | Phase 1 | Completed | Omeicos Therapeutics GmbH | 75 | 2017-02-08 | 2018-09-28 |
| A Study of IMR-687 in Healthy Adult Volunteers IMR-687, Placebo Oral Capsule - Sickle Cell Disease, Sickle-Cell; Hb-SC | Phase 1 | Completed | Cardurion Pharmaceuticals, Inc. | 66 | 2016-10-18 | 2025-05-15 |
| Phase 1 Study of NPT200-11 in Healthy Subjects NPT200-11, Placebo - Healthy Volunteers | Phase 1 | Completed | Neuropore Therapies Inc. | 55 | 2015-07-01 | 2016-02-15 |
| Improving Buprenorphine Detoxification Outcomes With Isradipine Isradipine, Placebo - Opioid Dependence | Phase 1 / Phase 2 | Completed | University of Arkansas | 28 | 2013-10-01 | 2017-06-05 |
Showing 20 of 23. Sign in to see all of them.
Anemia, Sickle Cell (2) · Diabetes Mellitus (2) · Opioid-Related Disorders (2) · Alzheimer Disease (1) · Atrial Fibrillation (1) · Autism Spectrum Disorder (1) · Autoimmune Diseases (1) · Bone Diseases, Metabolic (1) · COVID-19 (1) · Cocaine-Related Disorders (1) · Depression (1) · Dyslipidemias (1) · Gastrointestinal Diseases (1) · Hemoglobin SC Disease (1) · Hemostatic Disorders (1)
Xenon Pharmaceuticals Inc. (2) · Yale University (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Cardurion Pharmaceuticals, Inc. (1) · Charite University, Berlin, Germany (1) · Columbia University (1) · Generian Pharmaceuticals, Inc. (1) · Immunomolecular Therapeutics, Inc. (1) · Indiana University (1) · Lohocla Research Corporation (1) · Microbiotix, Inc. (1) · Neuralstem Inc. (1) · Neuropore Therapies Inc. (1) · Omeicos Therapeutics GmbH (1) · Temple University (1)
United States (13) · United Kingdom (3) · Germany (2) · Bangladesh (1) · China (1) · Mexico (1)
Alison Oliveto, PhD (1) · Arya Mani, MD (1) · Bess Dawson-Hughes, MD (1) · Danielle Armas, M.D. CPI (1) · Frank Schaumann, Dr. med (1) · Gregory Beatch, PhD (1) · Gregory J Tracey, MD (1) · Gregory N Beatch, PhD (1) · Jared R Brosch, MD (1) · Joshua R Cook, MD, PhD (1) · Karl Johe, PhD (1) · Mark Wallace, MD (1)
PMID 29229209, PMID 33281447, PMID 38601830, PMID 39329240, PMID 40324978, PMID 41225660
2017 (2), R21AR074138 (1), R21DA035325 (1), R44AA024905 (1), R44DA018515 (1), U01DA048517 (1)